The EU has registered medicines against Alzheimer’s disease: Details

The drug will be able to use patients with early signs of Alzheimer’s disease

Photo: Andrewlozovyi/Depositphotos

The European Union was allowed to use Leqmbi to treat patients with mild cognitive disorders in the early stages of Alzheimer’s disease.

The decision to register the drug European Commission has made after two years of consideration, informs Reuters.

This makes the drug the first approved drug in the EU, which is probably aimed at the main cause of the disease-proteins called beta-amyloid in the brain.

The permit assumes that Leqmbi can be used to treat people who have one or no copies of the Apoe4 gene, as well as sticky clots of beta-amyloid protein in the brain. According to analyst William Blair, the decision to exclude from the list of possible patients with two copies of this gene is explained by safety warnings.

The decision of the European Commission corresponds to the position of the European Agency for Medicines, which confirmed that the drug should be approved for a narrower range of patients than those who tested the drug.

Leqmbi is currently approved for use in patients with two copies of this gene in the United States, but such patients should undergo regular brain scanning during treatment in order to control the potential swelling of the organ.

Also, Alzheimer’s disease is registered in Japan, China, the United Kingdom and several other markets.

Previous trial Eisai and Biogen drugs have shown that patients who have taken them had a decrease in cognitive disorders, including memory and thinking. Within 18 months of testing, the patient’s condition improved by 27%.

The results have shown that the drug reduces toxic plaques in the brain and improves patients’ ability to perform daily tasks.

At the same time, approximately a fifth of the test participants had side effects, including brain swelling and brain bleeding. Another 3% of patients found symptomatic side effects of drugs.

Previously, scientists have discovered Five biological variants of illness Alzheimer, which are associated with the probable cause of illness.